Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  1998-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.98.17.1742PMID 9788828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The anaerobic threshold measurement to evaluate exercise performance.

  2015cited by this paper
• Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy.

  1998cited by this paper
• Skeletal muscle myosin heavy chains in heart failure: correlation between magnitude of the isozyme shift, exercise capacity, and gas exchange measurements.

  1998cited by this paper
• The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure.

  1997cited by this paper
• Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure.

  1997cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997cited by this paper
• Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure.

  1996cited by this paper
• Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.

  1996cited by this paper
• Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity.

  1996cited by this paper
• Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril.

  1996cited by this paper
• Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis.

  1996cited by this paper
• Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure.

  1996cited by this paper
• Low intensity exercise training in patients with chronic heart failure.

  1995cited by this paper
• Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.

  1995cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Controlled Trial of Physical Training in Chronic Heart Failure, Exercise Performance, Hemodynamics, Ventilation, and Autonomic Function.

  1994cited by this paper
• Insulin resistance in chronic heart failure.

  1994cited by this paper
• Skeletal muscle size: relationship to muscle function in heart failure.

  1993cited by this paper
• Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure

  1993cited by this paper
• Regional specificity of peak hyperemic response in patients with congestive heart failure: correlation with peak aerobic capacity.

  1993cited by this paper
• Are alterations of skeletal muscle ultrastructure in patients with heart failure reversible under treatment with ACE-inhibitors?

  1993cited by this paper
• Calcium in Muscle Contraction: Cellular and Molecular Physiology

  1992cited by this paper
• Contribution of Skeletal Muscle Atrophy to Exercise Intolerance and Altered Muscle Metabolism in Heart Failure

  1992cited by this paper
• Alterations of Skeletal Muscle in Chronic Heart Failure

  1992cited by this paper
• Isolated ventricular myocytes from failing and non-failing human heart; the relation of age and clinical status of patients to isoproterenol response.

  1992cited by this paper
• A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril

  1992cited by this paper
• Neurophysiological Assessment of Skeletal Muscle Fatigue in Patients With Congestive Heart Failure

  1992cited by this paper
• Controlled Trial of Physical Training in Chronic Heart Failure: Exercise Performance, Hemodynamics, Ventilation, and Autonomic Function

  1992cited by this paper
• Calcium in Muscle Contraction

  1992cited by this paper
• Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.

  1991cited by this paper
• Access of peripherally administered DuP 753 to rat brain angiotensin II receptors

  1991cited by this paper
• Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance.

  1991cited by this paper
• Training-induced skeletal muscle adaptations are independent of systemic adaptations.

  1990cited by this paper
• Skeletal muscle response to exercise training in congestive heart failure.

  1990cited by this paper
• Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure.

  1990cited by this paper
• Skeletal muscle metabolism in heart failure: a 31P nuclear magnetic resonance spectroscopy study of leg muscle.

  1990cited by this paper
• Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance.

  1989cited by this paper
• Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure.

  1989cited by this paper
• Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure.

  1989cited by this paper
• Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance.

  1988cited by this paper
• Abnormalities of skeletal muscle in patients with chronic heart failure.

  1988cited by this paper
• Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities.

  1988cited by this paper
• Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure. Evidence for abnormalities unrelated to blood flow.

  1988cited by this paper
• 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure.

  1987cited by this paper
• Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow.

  1987cited by this paper
• Exercise ventilation and pulmonary artery wedge pressure in chronic stable congestive heart failure.

  1986cited by this paper
• Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow.

  1986cited by this paper
• Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance.

  1985cited by this paper
• Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle.

  1984cited by this paper
• A sensitive SDS-PAGE method separating myosin heavy chain isoforms of rat skeletal muscles reveals the heterogeneous nature of the embryonic myosin.

  1983cited by this paper
• Significance of skeletal muscle oxidative enzyme enhancement with endurance training.

  1982cited by this paper
• Biochemical adaptations to endurance exercise in muscle.

  1976cited by this paper

• COMT and ACE (Epi)genetic Variation Is Associated with Cognitive and Metabolic Resilience in Swiss Tactical Athletes

  2026cites this paper
• The 70 year Odyssey of exercise training based cardiac rehabilitation with respect to medical innovations in heart failure

  2026cites this paper
• Influence of exercise and nutrition on sarcopenia in cardiovascular disease: A Scientific Statement of the European Association of Preventive Cardiology of the ESC.

  2025cites this paper
• Angiotensin-converting enzyme and exercise adaptations: Genetic variability, pharmacological modulation and future directions.

  2025cites this paper
• Muscle mass, muscle strength and the renin-angiotensin system.

  2024cites this paper
• Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium

  2024cites this paper
• Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians

  2024cites this paper
• Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints

  2024cites this paper
• The angiotensin-converting enzyme I/D polymorphism does not impact training-induced adaptations in exercise capacity in patients with stable coronary artery disease

  2023cites this paper
• Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

  2023cites this paper
• ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial

  2023cites this paper
• Effects of losartan and exercise on muscle mass and exercise endurance of old mice.

  2022cites this paper
• Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat Aging Model

  2022cites this paper
• Angiotensin receptor blockers use and changes in frailty, muscle mass, and function indexes: Singapore Longitudinal Ageing Study

  2021cites this paper
• High serum angiotensin-converting enzyme 2 activity as a biomarker of frailty in nursing home residents.

  2021cites this paper
• Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia.

  2021cites this paper
• Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure.

  2021cites this paper
• Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science

  2020cites this paper
• Sarcopenia

  2020cites this paper
• COVID-19 and the Renin Angiotensin System: Implications for the Older Adults

  2020cites this paper
• Very early changes in quality of life after transcatheter aortic valve replacement: Results from the 3M TAVR trial.

  2020cites this paper
• Alterations in Skeletal Muscle in Heart Failure

  2020cites this paper
• Increased functional capacity after 12 weeks of exercise training does not transform into improved skeletal muscle metabolism or ultrastructure in heart failure patients on modern optimal medical therapy.

  2020cites this paper
• Skeletal Muscle Myopathy in Heart Failure: the Role of Ejection Fraction

  2018cites this paper
• Fatigue: A Complex Symptom and its Impact on Cancer and Heart Failure

  2018cites this paper
• Cardiac expression of neutrophil gelatinase‐associated lipocalin in a model of cancer cachexia‐induced cardiomyopathy

  2018cites this paper
• Fadiga: Um Sintoma Complexo e seu Impacto no Câncer e na Insuficiência Cardíaca

  2018cites this paper
• Losartan has no additive effect on the response to heavy-resistance exercise in human elderly skeletal muscle.

  2018cites this paper
• Treatments for Heart Failure

  2017cites this paper
• Relationship of quadriceps muscle power and optimal shortening velocity with angiotensin-converting enzyme activity in older women

  2017cites this paper
• Angiotensin-II blockage, muscle strength, and exercise capacity in physically independent older adults

  2016cites this paper
• Genetic Influences on Functional Capacities in Aging.

  2016cites this paper
• Neuromuscular junction fragmentation and muscle wasting in heart failure: a sharp cut from a Sica sword?

  2015cites this paper
• Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?

  2015cites this paper
• with left ventricular dysfunction energy release during supramaximal effort in patients Anaerobic and aerobic relative contribution to total

  2015cites this paper
• Treating sarcopenia in older and oldest old.

  2015cites this paper
• Skeletal Muscle Changes in Chronic Cardiac Disease and Failure.

  2015cites this paper
• Effect of aerobic interval training on pathological remodelling and mitochondrial dysfunction in the post-infarction failing rat heart

  2015cites this paper
• in muscle oxidative capacity or contractile phenotype response to endurance training in rats, without change Decreased muscle ACE activity enhances functional

  2015cites this paper
• Skeletal muscle myofilament adaptations to aging, disease, and disuse and their effects on whole muscle performance in older adult humans

  2014cites this paper
• Losartan improves measures of activity, inflammation, and oxidative stress in older mice.

  2014cites this paper
• The contribution of stem cell therapy to skeletal muscle remodeling in heart failure.

  2013cites this paper
• Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies.

  2013cites this paper
• ACE-inhibition and skeletal muscle dysfunction in chronic obstructive pulmonary disease

  2013cites this paper
• Effects of Combination of AT 1 -Antagonist Candesartan Cilexetil and AСЕ-Inhibitors in Patients with Congestive Heart Failure

  2013cites this paper
• Intact skeletal muscle mitochondrial enzyme activity but diminished exercise capacity in advanced heart failure patients on optimal medical and device therapy

  2013cites this paper
• Effect of Ramipril on Walking Times and Quality of Life Among Patients With Peripheral Artery Disease and Intermittent Claudication

  2013cites this paper
• Metabolic and structural impairment of skeletal muscle in heart failure

  2013cites this paper
• Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

  2013cites this paper
• Exercise Intolerance in Chronic Heart Failure – Skeletal Muscle Dysfunction and Potential Therapies –

  2013cites this paper
• Effects of combination of AT1-antagonist candesartan cilexetil and ACE-inhibitors in patients with congestive heart failure.

  2013cites this paper
• The mechanisms of muscle wasting in COPD and heart failure

  2012cites this paper
• Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials

  2012cites this paper
• The Future of Drug Treatments

  2012cites this paper
• Nutrition, Protein Turnover and Muscle Mass

  2012cites this paper
• Angiotensin II Receptor Antagonists in Chronic Heart Failure

  2012cites this paper
• Chapter 45 – Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure

  2011cites this paper
• The epidemiology of sarcopenia in community living older adults: what role does lifestyle play?

  2011cites this paper
• Sarcopenia

  2011cites this paper
• Physiopathological mechanism of sarcopenia.

  2011cites this paper
• Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?

  2011cites this paper
• Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: influence of losartan.

  2011cites this paper
• Chapter 19 – Alterations in Diaphragmatic and Skeletal Muscle in Heart Failure

  2011cites this paper
• CHAPTER 73 – Sarcopenia

  2010cites this paper
• Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree?

  2010cites this paper
• Training effects on skeletal muscle calcium handling in human chronic heart failure.

  2010cites this paper
• Making the Case for Skeletal Myopathy as the Major Limitation of Exercise Capacity in Heart Failure

  2010cites this paper
• Hypertension Update and Cardiovascular Risk Reduction in Physically Active Individuals and Athletes

  2010cites this paper
• Latissimus dorsi fine needle muscle biopsy: a novel and efficient approach to study proximal muscles of upper limbs.

  2010cites this paper
• HIGHLIGHTED TOPIC Regulation of Protein Metabolism in Exercise and Recovery Decreased muscle ACE activity enhances functional response to endurance training in rats, without change in muscle oxidative capacity or contractile phenotype

  2009cites this paper
• Physiopathological mechanism of sarcopenia

  2009cites this paper
• Physical Function Is Weakly Associated with Angiotensin-Converting Enzyme Gene I/D Polymorphism in Elderly Japanese Subjects

  2009cites this paper
• Validated treatments and therapeutic perspectives regarding physical activities

  2009cites this paper
• A transient antioxidant stress response accompanies the onset of disuse atrophy in human skeletal muscle.

  2009cites this paper
• Candesartan Improves Maximal Exercise Capacity in Hypertensives: Results of a Randomized Placebo‐Controlled Crossover Trial

  2009cites this paper
• Carla Task Force on Sarcopenia: Propositions for clinical trials

  2009cites this paper
• Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia

  2009influential citation
• アンジオテンシン I 変換酵素遺伝子挿入/欠失多型と身体能力

  2008cites this paper
• Keeping Pace with ACE

  2008cites this paper
• Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure?

  2008influential citation
• Randomized, placebo‐controlled, double‐blind pilot trial of ramipril in McArdle's disease

  2008cites this paper
• Anaerobic and aerobic relative contribution to total energy release during supramaximal effort in patients with left ventricular dysfunction.

  2008cites this paper
• Skeletal muscle myofibrillar protein oxidation and exercise capacity in heart failure

  2008influential citation
• Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives

  2008cites this paper
• [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].

  2008cites this paper
• ACE inhibitors as a therapy for sarcopenia — Evidence and possible mechanisms

  2008cites this paper
• Physiological basis for contractile dysfunction in heart failure.

  2008cites this paper
• Low agreement of ventilatory threshold between training modes in cardiac patients

  2007cites this paper
• Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial

  2007cites this paper
• Angiotensin I converting enzyme gene polymorphism and exercise trainability in elderly women: an electrocardiological approach.

  2007influential citation
• Variation in ACE activity affects myogenic differentiation in C2C12 cells.

  2007cites this paper
• Coxygenase-1: Studies in Humans and in an Animal Model Carnitine-Mediated Improved Response to Erythropoetin Involves Induction of Haem

  2007cites this paper
• Molecular Modifications Induced by Physical Exercise: A Significant Role in Disease Prevention

  2007cites this paper
• Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice.

  2007cites this paper
• Functional overload attenuates plantaris atrophy in tumor-bearing rats

  2007cites this paper
• Effects of ACE inhibitors on skeletal muscle.

  2006cites this paper
• Heart failure: a model of cardiac and skeletal muscle energetic failure

  2006cites this paper
• Is Myosin Ubiquitinisation a mechanism of skeletal muscle atrophy in heart failure? IS MYOSIN UBIQUITINISATION A MECHANISM OF SKELETAL MUSCLE ATROPHY IN HEART FAILURE?

  2006cites this paper
• Relationship between Angiotensin Converting Enzyme Gene I/D Polymorphism and Muscle Strength in Elderly

  2006cites this paper
• Skeletal muscle apoptosis in experimental heart failure: the only link between inflammation and skeletal muscle wastage?

  2006cites this paper